ArticleJournal of neurosurgery. Case lessons2025
Stem cell therapy for peripheral nerve injury: illustrative cases.
Article in Journal of neurosurgery. Case lessons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrating Cells, Biomaterials, and Advanced Engineering for Next-Generation Peripheral Nerve Repair.Cells, tissues, organs · 2026Review
- Regenerative medicine approaches for the treatment of peripheral nerve injuries: progress and challenges.Regenerative biomaterials · 2026Review
- Review
- The Role of Vascularization in Nerve Regeneration: Mechanistic and Therapeutic Perspectives.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStem cell therapy is undergoing rapid evolution, as evidenced by preclinical studies showcasing the successful promotion of peripheral nerve regeneration using various stem cell types. Despite the absence of clinical studies that demonstrate both efficacy and safety, there has been a notable increase in the number of commercial entities marketing and promoting stem cell therapies for peripheral nerve injury (PNI) directly to patients. OBSERVATIONS: The authors present the cases of 5 patients who sustained traumatic PNIs and received stem cell therapy via various routes of delivery (including intramuscular, perineural, intrathecal, and intravenous administration) prior to presenting to the authors for evaluation. No objective functional improvement was noted in any of these patients at long-term follow-up. LESSONS: High-quality studies and greater involvement of academic surgeons on social media platforms are essential in today's landscape to promote education, provide leadership, and foster meaningful engagement, ultimately ensuring the best possible treatment outcomes for patients regarding the role of stem cell therapies in PNIs. https://thejns.org/doi/10.3171/CASE24878.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.